Page last updated: 2024-10-24

carmustine and Ovarian Neoplasms

carmustine has been researched along with Ovarian Neoplasms in 21 studies

Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.

Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Research Excerpts

ExcerptRelevanceReference
"The growth inhibitory effects, the reduction of [3H]-TdR incorporation and the perturbation of the cell cycle induced by the new agent mitozolomide on the M14 human melanoma cell line and on the SW626 human ovarian cancer cell line were compared to those produced by BCNU."3.67Mitozolomide activity on human cancer cells in vitro. ( D'Incalci, M; Erba, E; Landoni, F; Lorico, A; Mangioni, C; Morasca, L; Pepe, S; Ubezio, P, 1986)
"In the human ovarian cancer lines SK-OV-3 and OAW 42, O6-AGT activity was 337."1.29Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU. ( Magull-Seltenreich, A; Zeller, WJ, 1995)
"on post-surgical spontaneous metastases of a non-immunogenic tumour."1.28Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour. ( Acerbis, G; Cleris, L; Formelli, F; Parmiani, G; Rodolfo, M, 1992)
"AC = adriamycin and cyclophosphamide in ovarian cancer."1.27Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide. ( Amunni, G; Bonazza, M; Branconi, F; Massi, GB; Mazzei, T; Scarselli, G, 1984)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-199010 (47.62)18.7374
1990's8 (38.10)18.2507
2000's3 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Perego, P1
Gatti, L1
Righetti, SC1
Beretta, GL1
Carenini, N1
Corna, E1
Dal Bo, L1
Tinelli, S1
Colangelo, D1
Leone, R1
Apostoli, P1
Lombardi, L1
Beggiolin, G1
Piazzoni, L1
Zunino, F1
Paik, J1
Duncan, T1
Lindahl, T1
Sedgwick, B1
D'Incalci, M2
Torti, L1
Damia, G1
Erba, E2
Morasca, L2
Garattini, S1
Cornbleet, MA1
Leonard, RC1
Smyth, JF1
Mazzei, T1
Bonazza, M1
Amunni, G1
Scarselli, G1
Branconi, F1
Massi, GB1
Presant, CA1
Bartolucci, A1
Magull-Seltenreich, A1
Zeller, WJ2
Strumberg, D1
Harstrick, A1
Doll, K1
Hoffmann, B1
Seeber, S1
Bernges, F1
Fruehauf, JP2
Zonis, S2
al-Bassam, M2
Kyshtoobayeva, A2
Dasgupta, C2
Milovanovic, T2
Parker, RJ2
Buzaid, AC2
Mandanas, RA1
Saez, RA1
Epstein, RB1
Confer, DL1
Selby, GB1
Bible, KC1
Boerner, SA1
Kirkland, K1
Anderl, KL1
Bartelt, D1
Svingen, PA1
Kottke, TJ1
Lee, YK1
Eckdahl, S1
Stalboerger, PG1
Jenkins, RB1
Kaufmann, SH1
Salmon, SE1
Hamburger, AW1
Soehnlen, B1
Durie, BG1
Alberts, DS1
Moon, TE1
Acerbis, G1
Cleris, L1
Rodolfo, M1
Parmiani, G1
Formelli, F1
Lau, DH1
Lewis, AD1
Ehsan, MN1
Sikic, BI1
Pepe, S1
Ubezio, P1
Lorico, A1
Mangioni, C1
Landoni, F1
Facchini, V1
Gadducci, A1
Bogi, G1
Colombi, L1
Basile, AG1
Ballantini, M1
De Pasquale, F1
Fioretti, P1
Marsh, JC1
DeConti, RC1
Hubbard, SP1
Jorgensen, EO1
Malkasian, GD1
Webb, MJ1
Hahn, RG1
Godfrey, TE1
King, A1
Rentschler, R1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352]Phase 222 participants (Actual)Interventional2012-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Response

Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months

Interventionmonths (Median)
Bendamustine/Ofatumumab5.6

Number of Patients With a Complete Response

Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab7

Number of Patients With Treatment-Related Adverse Events (AEs) as a Measure of Safety

A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab16

Overall Response (OR)

Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months

InterventionParticipants (Count of Participants)
Bendamustine/Ofatumumab19

Overall Survival (OS)

Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months

Interventionmonths (Median)
Bendamustine/Ofatumumab12.0

Progression-free Survival

Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Interventionmonths (Median)
Bendamustine/Ofatumumab8.6

Time to Progression (TTP)

Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months

Interventionmonths (Median)
Bendamustine/Ofatumumab10.5

Reviews

1 review available for carmustine and Ovarian Neoplasms

ArticleYear
High-dose alkylating agent therapy: a review of clinical experiences.
    Cancer drug delivery, 1984,Summer, Volume: 1, Issue:3

    Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug;

1984

Trials

3 trials available for carmustine and Ovarian Neoplasms

ArticleYear
Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
    Bone marrow transplantation, 1998, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplati

1998
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents;

1971
Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
    American journal of obstetrics and gynecology, 1973, Jul-15, Volume: 116, Issue:6

    Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Injections, Intravenous; Ova

1973

Other Studies

17 other studies available for carmustine and Ovarian Neoplasms

ArticleYear
Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    International journal of cancer, 2003, Jul-10, Volume: 105, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Base Pair Mismatch; Carmustine; Checkpoint Kinase 1; Cisplatin; Cy

2003
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
    Cancer research, 2005, Nov-15, Volume: 65, Issue:22

    Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Ge

2005
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
    Cancer research, 1983, Volume: 43, Issue:12 Pt 1

    Topics: Animals; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Cyclophosphamide; Dacarbazine; Dr

1983
Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1984, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine;

1984
Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
    Medical and pediatric oncology, 1983, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycloph

1983
Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cystadenocarcinoma,

1995
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine

1996
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.
    Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Survival; Cisplatin; DNA D

1996
Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Pigment cell research, 1997, Volume: 10, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Buthionine Sul

1997
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
    Chemico-biological interactions, 1998, Apr-24, Volume: 111-112

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine

1998
Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Carmustine; Chromosome Aberrations; Chromosome Mapping; Cisplatin; DNA Adduct

2000
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
    The New England journal of medicine, 1978, Jun-15, Volume: 298, Issue:24

    Topics: Antineoplastic Agents; Bleomycin; Carmustine; Clone Cells; Doxorubicin; Drug Resistance; Female; Hem

1978
Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
    Cancer immunology, immunotherapy : CII, 1992, Volume: 34, Issue:6

    Topics: Animals; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administratio

1992
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Cancer research, 1991, Oct-01, Volume: 51, Issue:19

    Topics: Bleomycin; Blotting, Western; Carmustine; Cisplatin; Cross Reactions; Dinitrochlorobenzene; DNA; DNA

1991
Mitozolomide activity on human cancer cells in vitro.
    British journal of cancer, 1986, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Dose-Response Relationship, Drug; Fe

1986
Polychemotherapy with carmustine, cyclophosphamide plus adriamycin in the treatment of advanced ovarian cancer.
    European journal of gynaecological oncology, 1985, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine;

1985
1,3-Bis (2-chloroethyl)-1-nitrosourea: effects on advanced ovarian carcinoma.
    American journal of obstetrics and gynecology, 1973, Feb-15, Volume: 115, Issue:4

    Topics: Adult; Aged; Blood Platelets; Carmustine; Cystadenocarcinoma; Drug Resistance; Female; Humans; Leuko

1973